We are pleased to participate to the 21st International Congress of the European Society of Toxicology In Vitro (ESTIV 2022), which will take place in Barcelona-Sitges, Spain, from 21st to 25th November 2022. Our project Leader in in vitro pharmacology Véronique De Conto will present her poster entitled “In vitro microenvironment modifies the neurotoxic Read more…
About 90% of drug candidates fail in clinical trials, for efficacy- and toxicity-related reasons, which often involve the Central Nervous System (CNS). This high failure rate highlights a lack of relevance in experimental models used upstream, including human in vitro models. Indeed, they do not take into account the complexity Read more…
From different studies we know that more than 92% of drug candidates for Central Nervous System diseases fail in clinical trials, with 34% of safety failure. All that candidates have successfully passed in vitro steps and animal testing. Conclusion is straightforward : we have to deeply change biological models in Read more…
Présentation en français About 90% of drug-candidates failed in clinical trials, in particular in neurology, due to a lack of efficacy. That highlights a lack of relevance in preclinical models, including in vitro models, which do not take into account the microenvironment, composed by glial cells and the Extracellular Matrix Read more…
Presentation in english Environ 90 % des candidats médicaments échouent aux essais cliniques, notamment en neurologie, faute d’efficacité. Cela met en évidence un manque de pertinence dans les modèles précliniques, y compris les modèles in vitro, qui ne prennent pas en compte le microenvironnement, composé par les cellules gliales et Read more…
The Federation of European Neuroscience Societies (FENS) forum 2022 took place in Paris, from 9 to 15 July. This event gathers nearly 8,000 neuroscientists from 92 countries. Twenty-two plenary and special lectures were given in 8 conferences room, about various topics in neurosciences, like brain imaging methods, brain development (synapse Read more…
We are very pleased to talk with Pr Robert-Alain Toillon from University of Lille about his uses of BIOMIMESYS® technology in oncology and more specificaly on breast cancer. English is below Je m’appelle Robert-Alain Toillon je travaille au laboratoire Canther dans l’institut OncoLille sur le cancer du sein et plus Read more…
Aim: About 90% of drug-candidates failed in clinical trials, in particular in neurology, due to a lack of efficacy. That highlights a lack of relevance in preclinical models, including in vitro models, which do not take into account the microenvironment, composed by glial cells and the Extracellular Matrix (ECM). The Read more…
Our project leader in in vitro pharmacology Veronique De Conto will be present to the Federation of European Neurosciences Societies (FENS) congress, from 9 to 13 July in Paris. She will present a poster about the importance of microenvironment in cerebral in vitro models for phenotypic screening, in the frame Read more…
Elodie Vandenhaute (our project director), Véronique De Conto (our project leader in in vitro pharmacology) and Natacha Perrin (our trainee in neurosciences) were present at the annual SCMC (Société Cerveau et Maladies Cérébrovasculaires – The French Brain and Cerebrovascular Diseases Society) congress, which took place on the 16th of June Read more…
Thursday, 16th June will take place the annual congress of the SCMC (Societe Cerveau et Maladies Cerebrovasculaires – Brain and cerebrovascular diseases Society) in Paris. It is our pleasure to participate to this event! Indeed, our project director Elodie Vandenhaute will be present as secretary of the association and organizer Read more…
In the context of NanoStem Project, a Marie-Curie Innovative Training Network project funded by the European Union’s Horizon 2020, and in collaboration with HCS Pharma, Elisa L.J. Moya defensed successfully her PhD the 15th December 2021 in Université d’Artois (Lens, France) about the miniaturization and automation of a well-established human Read more…
About 90% of drug candidates fail in clinical trials, for efficacy- and toxicity-related reasons, which often involve the Central Nervous System (CNS). This high failure rate highlights a lack of relevance in experimental models used upstream, including human in vitro models. Indeed, they do not take into account the complexity Read more…
2022 is beginning, but 2021 ended in the most beautiful way… with Véronique De Conto‘s PhD defense. She successfully defended her PhD thesis about the importance of the microenvironment in cerebral in vitro models for phenotypic screening. We had the privilege to maintain the PhD defense on-site, even if one member Read more…
2D cell culture has been used for more than 100 years now, to keep cells outside of their original organism and to use them for different purposes. It is still widely used in research and early steps of the drug discovery process, and has allowed a bunch of discoveries so Read more…
As you might know, October is the Breast Cancer Awareness Month, an annual campaign to raise awareness about the impact of breast cancer. Research is the key tool to fight this disease and we are very happy to collaborate with amazing research teams in this fight. Since last year, our Read more…
Since the beginning of this year we have created four webinars to present our BIOMIMESYS® technology and practical uses. We have chosen to focus on the scientific side of our innovation by presenting results in drug discovery or dermocosmetology domains. Theses four webinars are available on our support page (with many Read more…
Pharmaceutical industry is facing a very high failure rate in drug discovery, with 90% of failure in clinical trials. This is particularly true for central nervous system applications, with a rate of 30% safety failure in clinical trials, compared to 7% in preclinical trials (Cook et al. 2014). This reveals Read more…
The annual congress of the SCMC (Societé Cerveau et Maldies Cérébraux Vasculaires – Brain and cerebrovascular diseases Society) will take place this Friday, may 28 2021 (virtual congress). On this occasion, our PhD student Véronique De Conto will present her PhD works, which concern the development of new cerebral in Read more…
Ask for high quality link by putting your email below There is a 90% failure in clinical trials, due to efficacy and safety issues, which frequently concerns the central nervous system. That points a lack of relevance of preclinical models used upstream. In this frame, the aim of this study Read more…
